Gilead Sciences sees increased EPS estimates and focus on community access

Erste Group Bank has increased its fiscal year 2026 earnings per share (EPS) estimate for Gilead Sciences to ($0.44), up from a previous estimate of ($0.45). The current consensus estimate for the company's full-year earnings stands at ($0.48) per share.

Other recent analyst actions include Morgan Stanley adjusting its price target to $165.00 with an “overweight” rating, and Zacks Research upgrading the company to a “strong-buy” rating. The stock currently holds a consensus rating of “Moderate Buy” with an average target price of $158.78.

Separately, Peter Wickersham, Vice President and General Manager of Gilead Sciences for the UK and Ireland, emphasized the importance of community engagement in bridging the gap between medical innovation and real-world access. Wickersham noted that successful public health outcomes, such as England’s hepatitis C elimination initiative, require collaborating with stakeholders like drug treatment centers and prisons to bring services directly to the people.